JP7709917B2 - コネキシン４３抗体およびその使用 - Google Patents

コネキシン４３抗体およびその使用

Info

Publication number
JP7709917B2
JP7709917B2 JP2021545713A JP2021545713A JP7709917B2 JP 7709917 B2 JP7709917 B2 JP 7709917B2 JP 2021545713 A JP2021545713 A JP 2021545713A JP 2021545713 A JP2021545713 A JP 2021545713A JP 7709917 B2 JP7709917 B2 JP 7709917B2
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding
weeks
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021545713A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022519293A (ja
JPWO2020163353A5 (enExample
Inventor
ヤンフェン ジャン，
Original Assignee
アラマブ セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アラマブ セラピューティクス， インコーポレイテッド filed Critical アラマブ セラピューティクス， インコーポレイテッド
Publication of JP2022519293A publication Critical patent/JP2022519293A/ja
Publication of JPWO2020163353A5 publication Critical patent/JPWO2020163353A5/ja
Priority to JP2025036066A priority Critical patent/JP2025090679A/ja
Application granted granted Critical
Publication of JP7709917B2 publication Critical patent/JP7709917B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Computer And Data Communications (AREA)
JP2021545713A 2019-02-04 2020-02-04 コネキシン４３抗体およびその使用 Active JP7709917B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025036066A JP2025090679A (ja) 2019-02-04 2025-03-07 コネキシン４３抗体およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962800869P 2019-02-04 2019-02-04
US62/800,869 2019-02-04
PCT/US2020/016606 WO2020163353A1 (en) 2019-02-04 2020-02-04 Connexin 43 antibodies and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025036066A Division JP2025090679A (ja) 2019-02-04 2025-03-07 コネキシン４３抗体およびその使用

Publications (3)

Publication Number Publication Date
JP2022519293A JP2022519293A (ja) 2022-03-22
JPWO2020163353A5 JPWO2020163353A5 (enExample) 2023-02-13
JP7709917B2 true JP7709917B2 (ja) 2025-07-17

Family

ID=71947290

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021545713A Active JP7709917B2 (ja) 2019-02-04 2020-02-04 コネキシン４３抗体およびその使用
JP2025036066A Pending JP2025090679A (ja) 2019-02-04 2025-03-07 コネキシン４３抗体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025036066A Pending JP2025090679A (ja) 2019-02-04 2025-03-07 コネキシン４３抗体およびその使用

Country Status (9)

Country Link
US (2) US12187794B2 (enExample)
EP (1) EP3920969A4 (enExample)
JP (2) JP7709917B2 (enExample)
KR (1) KR20210153039A (enExample)
CN (2) CN119700967A (enExample)
AU (2) AU2020219112A1 (enExample)
CA (1) CA3128987A1 (enExample)
IL (2) IL285369B2 (enExample)
WO (1) WO2020163353A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019195273A1 (en) 2018-04-02 2019-10-10 Alamab Therapeutics, Inc. Connexin 43 antibodies and use thereof
WO2022026914A1 (en) * 2020-07-31 2022-02-03 Alamab Therapeutics, Inc. Anti-connexin antibody formulations
WO2025006774A1 (en) * 2023-06-30 2025-01-02 Alamab Therapeutics, Inc. Method of treating osteoarthritis

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007513633A (ja) 2003-12-10 2007-05-31 メダレックス インコーポレイテッド インターフェロンα抗体及びその使用
JP2011523414A (ja) 2008-05-15 2011-08-11 バイオジェン・アイデック・エムエイ・インコーポレイテッド 抗ｆｎ１４抗体、およびその使用
WO2015027120A1 (en) 2013-08-21 2015-02-26 Jiang Jean X Compositions and methods for targeting connexin hemichannels
WO2017147561A1 (en) 2016-02-26 2017-08-31 The Board Of Regents Of The University Of Texas System CONNEXIN (Cx) 43 HEMICHANNEL-BINDING ANTIBODIES AND USES THEREOF

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
SG48760A1 (en) 1992-07-24 2003-03-18 Abgenix Inc Generation of xenogenetic antibodies
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
AU2002362197A1 (en) * 2001-12-28 2003-07-24 Chugai Seiyaku Kabushiki Kaisha Method of stabilizing protein
US6745478B2 (en) 2002-07-18 2004-06-08 Delillo Dominick D. Multi-purpose work knife
KR20150004906A (ko) 2005-02-03 2015-01-13 코다 테라퓨틱스 (엔지) 리미티드 항-코넥신 화합물 및 그의 용도
CN102099475A (zh) 2008-06-04 2011-06-15 科达治疗公司 用间隙连接调节化合物治疗疼痛
CN103429732B (zh) 2010-12-27 2015-09-16 Lsip基金运营联合公司 iPS细胞及其制造方法
US9493552B2 (en) 2013-11-15 2016-11-15 China Synthetic Rubber Corporation Therapeutic biologic for treatment of hepatocellular carcinoma
EP4491184A3 (en) 2014-08-22 2025-03-26 Auckland Uniservices Limited Channel modulators
WO2017024465A1 (en) * 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
WO2019195273A1 (en) 2018-04-02 2019-10-10 Alamab Therapeutics, Inc. Connexin 43 antibodies and use thereof
WO2022026914A1 (en) * 2020-07-31 2022-02-03 Alamab Therapeutics, Inc. Anti-connexin antibody formulations

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007513633A (ja) 2003-12-10 2007-05-31 メダレックス インコーポレイテッド インターフェロンα抗体及びその使用
JP2011523414A (ja) 2008-05-15 2011-08-11 バイオジェン・アイデック・エムエイ・インコーポレイテッド 抗ｆｎ１４抗体、およびその使用
WO2015027120A1 (en) 2013-08-21 2015-02-26 Jiang Jean X Compositions and methods for targeting connexin hemichannels
WO2017147561A1 (en) 2016-02-26 2017-08-31 The Board Of Regents Of The University Of Texas System CONNEXIN (Cx) 43 HEMICHANNEL-BINDING ANTIBODIES AND USES THEREOF

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
RIQUELME, Manuel A. et al.，Neuropharmacology，2013年12月，Vol. 75，pp. 525-532，DOI: 10.1016/j.neuropharm.2013.02.021
SILLER-JACKSON, Arlene J. et al.，Journal of Biological Chemistry，2008年09月26日，Vol. 283, No. 39，pp. 26374-26382，DOI: 10.1074/jbc.M803136200

Also Published As

Publication number Publication date
US12187794B2 (en) 2025-01-07
AU2022218583A1 (en) 2022-10-06
AU2020219112A1 (en) 2021-08-26
IL320816A (en) 2025-07-01
WO2020163353A1 (en) 2020-08-13
EP3920969A1 (en) 2021-12-15
US20250230233A1 (en) 2025-07-17
IL285369B2 (en) 2025-10-01
EP3920969A4 (en) 2022-11-30
JP2022519293A (ja) 2022-03-22
US20220411494A1 (en) 2022-12-29
CN119700967A (zh) 2025-03-28
IL285369B1 (en) 2025-06-01
KR20210153039A (ko) 2021-12-16
AU2022218583B9 (en) 2025-12-04
CN112384244A (zh) 2021-02-19
IL285369A (en) 2021-09-30
JP2025090679A (ja) 2025-06-17
CA3128987A1 (en) 2020-08-13
CN112384244B (zh) 2025-01-24

Similar Documents

Publication Publication Date Title
JP7550251B2 (ja) 糖尿病黄斑浮腫の治療のための組成物および方法
CN111704672B (zh) 抗血浆激肽释放酶抗体
CN105263514B (zh) 抗铁调素抗体及其用途
JP7437317B2 (ja) コネキシン４３抗体およびその使用
JP2025090679A (ja) コネキシン４３抗体およびその使用
JP2017512790A5 (enExample)
HK40043616A (en) Connexin 43 antibodies and use thereof
HK40043616B (zh) 连接蛋白43抗体及其用途
HK40042791A (en) Connexin 43 antibodies and use thereof
NZ618046B2 (en) Fc RECEPTOR BINDING PROTEINS

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230203

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230203

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240701

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241008

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250307

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250609

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250707

R150 Certificate of patent or registration of utility model

Ref document number: 7709917

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150